30 Jun 2014 07:00
For immediate release | 30 June 2014 |
ABCAM PLC
("Abcam" or "the Company")
Directorate Change
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools, announces that, after five years as Abcam's Chairman, Mike Redmond has decided to step down from the Board following the Annual General Meeting, which will be held later this year. He will be succeeded as Chairman by Murray Hennessy, who has served as a Non-Executive Director at Abcam for the past three years.
Jonathan Milner, Abcam's Chief Executive Officer, said:"Mike's insight and leadership have been instrumental for Abcam's successful growth over the past five years. On behalf of the Board I would like to extend our sincerest thanks and gratitude to him. After three years on the Board, Murray knows Abcam very well and his experience in international customer-facing industries and online businesses in particular make him the ideal candidate to take over from Mike later in the year and help lead Abcam's next phase of growth."
Abcam | + 44 (0) 1223 696 000 |
Jonathan Milner, Chief Executive Officer Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 130,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported by detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com